SCHEMBL7534877

SCHEMBL7534877

Cc1cc(C=NNC(=O)c2[nH]c3ccccc3c2-c2ccccc2)oc1C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 0.55
KMT2A Q03164 8/20 0.55
CRHBP P24387 1/20 0.55
CRHR2 Q13324 1/20 0.55
MAPT P10636 10/20 0.54
LMNA P02545 6/20 0.54
ALDH1A1 P00352 8/20 0.53
HPGD P15428 3/20 0.53
PAX8 Q06710 2/20 0.53
GAA P10253 2/20 0.53
KDM4E B2RXH2 6/20 0.51
SMN1; SMN2 Q16637 3/20 0.50
RAB9A P51151 1/20 0.50
TP53 P04637 1/20 0.50
POLB P06746 1/20 0.50
GFER P55789 1/20 0.48
RCE1 Q9Y256 1/20 0.48
TUBB4A P04350 2/20 0.48
TUBB P07437 2/20 0.48
TUBA3C P0DPH7 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7561442 1.00 MEN1 (0.55) MEN1KMT2ACRHBPCRHR2MAPT
SCHEMBL7560227 0.85 MAPT (0.61) MEN1KMT2ACRHBPCRHR2MAPT
SCHEMBL7560230 0.85 MAPT (0.61) MEN1KMT2ACRHBPCRHR2MAPT
SCHEMBL7559759 0.84 MAPT (0.54) MEN1KMT2ACRHBPCRHR2MAPT
SCHEMBL7559761 0.84 MAPT (0.54) MEN1KMT2ACRHBPCRHR2MAPT
SCHEMBL7561687 0.81 MAPT (0.58) MEN1KMT2ACRHBPCRHR2MAPT
SCHEMBL7561691 0.81 MAPT (0.58) MEN1KMT2ACRHBPCRHR2MAPT
SCHEMBL7530911 0.81 MAPK1 (0.62) MEN1KMT2ACRHBPCRHR2MAPT
SCHEMBL7560903 0.81 MAPK1 (0.62) MEN1KMT2ACRHBPCRHR2MAPT
SCHEMBL7560462 0.81 GAA (0.55) MEN1KMT2ACRHBPCRHR2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US claimed
WO-2002022576-A2 3-SUBSTITUTED INDOLE CARBOHYDRAZIDES USEFUL AS CELL PROLIFERATION AND ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2002-03-21 WO claimed
US-6323228-B1 INHIBITING ANGIOGENESIS IN A MAMMAL IN RECOGNIZED NEED OF SUCH TREATMENT COMPRISING ADMINISTERING TO THE MAMMAL WITH INDOLE SUBSTITUTED WITH HYDRAZIDES ABBOTT LABORATORIES 2001-11-27 US claimed
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US disclosed
WO-2002022576-A2 3-SUBSTITUTED INDOLE CARBOHYDRAZIDES USEFUL AS CELL PROLIFERATION AND ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2002-03-21 WO disclosed
US-6323228-B1 INHIBITING ANGIOGENESIS IN A MAMMAL IN RECOGNIZED NEED OF SUCH TREATMENT COMPRISING ADMINISTERING TO THE MAMMAL WITH INDOLE SUBSTITUTED WITH HYDRAZIDES ABBOTT LABORATORIES 2001-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors MKI67, FLT4, IDO1 MEN1 3165/4885KMT2A 2765/4885CRHBP 3797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.